HUTCHMED (China) Ltd
Business
HUTCHMED (China) Ltd is a global commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for oncology and immunological diseases. It markets internally discovered oncology drugs including savolitinib, fruquintinib and surufatinib, conducts clinical development of multiple small molecule and biologic candidates and advances a novel ATTC antibody‑targeted therapy conjugate platform. Its operations are organized into Oncology/Immunology R&D and commercial activities and Other Ventures comprising drug marketing, distribution and joint ventures. The company sells and distributes drugs primarily in China through an in‑house oncology sales force and hospital network, while leveraging global partnerships and licensing arrangements to conduct trials and commercialize products outside China.
Summary from filing dated 2025-03-19
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $548.51M |
| Net income | $456.91M |
| Total assets | $1.75B |
| Total liabilities | $501.83M |
| Stockholders' equity | $1.24B |
| Operating cash flow | $-64.66M |